Evidence mapPaperPMID 40664635Full record

ReviewCell death & disease2025

Anoikis resistance in gastric cancer: a comprehensive review.

Teresa D'Amore, Daniele Bravoco, Giuseppina Di Paola, Francesco Albano, Mariarita Brancaccio, Claudia Sabato, Giuseppe Cesta, Cinzia Zolfanelli, Vincenzo Lauciello, Geppino Falco and 1 more

Abstract readReview
In one paragraph

Review in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. PDIA6-SCD1 Axis Rewires Lipid Metabolism to Drive Gastric Cancer Progression.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Teresa D'Amore *Laboratory of Preclinical and Translational Research, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture, Italy.ORCID http://orcid.org/0000-0002-1435-4390
Daniele Bravoco *Biogem Scarl, Istituto di Ricerche Genetiche 'Gaetano Salvatore', Ariano Irpino, Italy.ORCID http://orcid.org/0009-0001-9305-5048
Giuseppina Di PaolaBiogem Scarl, Istituto di Ricerche Genetiche 'Gaetano Salvatore', Ariano Irpino, Italy.
Francesco AlbanoDepartment of Biology, University of Naples Federico II, Naples, Italy.ORCID http://orcid.org/0000-0001-6157-7688
Mariarita BrancaccioDepartment of Biology, University of Naples Federico II, Naples, Italy.
Claudia SabatoLaboratory of Preclinical and Translational Research, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture, Italy.ORCID http://orcid.org/0000-0001-7533-4660
Giuseppe CestaLaboratory of Preclinical and Translational Research, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture, Italy.
Cinzia ZolfanelliLaboratory of Preclinical and Translational Research, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture, Italy.
Vincenzo LaucielloLaboratory of Preclinical and Translational Research, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture, Italy.
Geppino FalcoBiogem Scarl, Istituto di Ricerche Genetiche 'Gaetano Salvatore', Ariano Irpino, Italy. geppino.falco@unina.it.
Pellegrino MazzoneBiogem Scarl, Istituto di Ricerche Genetiche 'Gaetano Salvatore', Ariano Irpino, Italy. pellegrino.mazzone@biogem.it.ORCID http://orcid.org/0000-0002-6217-1505

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastric cancer (GC) is a predominant malignant neoplasia responsible for cancer death worldwide. Because of the difficulty in early diagnosis as well as its high metastasis rate, GC shows an increasing incidence and poor prognosis. Conventional treatments for GC, such as chemotherapy, radiotherapy, and surgical resection, still fail to achieve curative effects because of drug resistance, a mechanism that leads to a reduction of 5-year survival for GC patients. Anoikis, a particular type of programmed cell death, is activated upon cancer cell detachment from the extracellular matrix, playing a crucial role in antagonizing the progression of several malignant tumors. Because GC cells metastasize mainly in the nearby sites in the peritoneum, a better comprehension of the molecular mechanisms involved in the anchorage-independent growth as well as metastatic spreading is crucial to counteract GC progression. In this context, this review critically examines the molecular mechanisms of anoikis, key pathways and regulatory networks, and the role of anoikis resistance in GC. Furthermore, it summarizes potential therapeutic strategies for targeting anoikis-resistant cells. By collecting and analyzing existing literature, this work aims to bridge gaps in the comprehension of the relation between anoikis resistance and GC pathophysiology, providing novel insights and directions for future research in this field.

Indexed as

AnoikisStomach NeoplasmsAnimalsDrug Resistance, NeoplasmHumans

Identifiers

PMID40664635
PMCPMC12264292

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.